iCo Therapeutics Inc. (iCo) is a Canada-based biotechnology company principally focused on the identification, development and commercialization of drug candidates to treat sight-and life-threatening diseases. The Company principally focuses on in-licensing drug candidates with a clinical history, and re-dose, reformulate and develop drug candidates for the treatment of sight-and life-threatening diseases. The Company's product candidates include iCo-007, iCo-008 and an Oral AmpB Delivery System. The Company has initiated Phase II clinical trial for iCo-007. iCo-008 is a human monoclonal antibody that is offered to treat sight threatening forms of allergic conjunctivitis by neutralizing eotaxin-1, a ligand to the chemokine receptor CCR3. Oral AmpB Delivery System is a toxic option for the treatment of serious systemic fungal infections. The Company has completed pre-clinical studies for iCo's Oral AmpB Delivery System.
Industry, Sector and Symbol:
Capitalization:- Market Cap: $3.38 million
- Outstanding Shares: 84,457,000
Average Prices:- 50 Day Moving Avg: $0.04
- 200 Day Moving Avg: $0.03
- 52 Week Range: $0.02 - $0.07
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.02 per share
- Price / Book: 2.00
Profitability:- EBIDTA: ($778,499.00)
- Return on Equity: -42.31%
- Return on Assets: -39.59%
Debt:- Current Ratio: 8.63%
- Quick Ratio: 8.63%
Misc:- Average Volume: 6,776 shs.
- Beta: 2.37
Frequently Asked Questions for Ico Therapeutics (OTCMKTS:ICOTF)
What is Ico Therapeutics' stock symbol?
Ico Therapeutics trades on the OTCMKTS under the ticker symbol "ICOTF."
How were Ico Therapeutics' earnings last quarter?
Who are some of Ico Therapeutics' key competitors?
Some companies that are related to Ico Therapeutics include Acura Pharmaceuticals (ACUR), Strata Skin Sciences (SSKN), Rosetta Genomics (ROSG), NeuroMetrix (NURO), Critical Outcome T (COTQF), Windtree Therapeutics (WINT), Affymax (AFFY), Adeptus Health (ADPT), Bayer AG (BAYRY), DNIB Unwind (BIND), Echo Therapeutics (ECTE), ELEKTA (EKTAY), Epirus Biopharmaceuticals (EPRS), Essilor International SA (ESLOY), Fresenius SE (FSNUY), Luxottica Group SpA (LUX), Mast Therapeutics (MSTX) and Parnell Pharmaceuticals Holdings Ltd (PARN).
Who are Ico Therapeutics' key executives?
Ico Therapeutics' management team includes the folowing people:
- William W. Jarosz J.D., Independent Chairman of the Board
- Andrew J. Rae, President, Chief Executive Officer, Director
- W. John Meekison, Chief Financial Officer, Corporate Secretary
- Peter Hnik M.D., Chief Medical Officer
- Richard William Barker, Independent Director
- Noel F. Hall, Independent Director
- Douglas Glen Janzen, Independent Director
How do I buy Ico Therapeutics stock?
Shares of Ico Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ico Therapeutics' stock price today?
One share of Ico Therapeutics stock can currently be purchased for approximately $0.04.
MarketBeat Community Rating for Ico Therapeutics (OTCMKTS ICOTF)MarketBeat's community ratings are surveys of what our community members think about Ico Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Ico Therapeutics (OTCMKTS:ICOTF) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Ico Therapeutics (OTCMKTS:ICOTF)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Ico Therapeutics (OTCMKTS:ICOTF)Earnings History by Quarter for Ico Therapeutics (OTCMKTS ICOTF)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/29/2014 | Q1 2014 | ($0.02) | ($0.01) | | | View | N/A |  |
| 4/24/2014 | Q4 2013 | ($0.02) | ($0.02) | | | View | N/A | |
| 11/27/2013 | Q3 | | ($0.01) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Ico Therapeutics (OTCMKTS:ICOTF)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Ico Therapeutics (OTCMKTS:ICOTF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Ico Therapeutics (OTCMKTS:ICOTF)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Ico Therapeutics (OTCMKTS:ICOTF)
Latest Headlines for Ico Therapeutics (OTCMKTS:ICOTF)
| Source: |
|
Ico Therapeutics (ICOTF) Chart for Friday, July, 28, 2017
